Emerald Bioscience (OTCMKTS:EMBI) Stock Price Down 6.6% – What’s Next?

Emerald Bioscience Inc. (OTCMKTS:EMBI)’s stock price dropped 6.6% during mid-day trading on Monday . The company traded as low as $0.6467 and last traded at $0.6603. Approximately 307,414 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.7070.

Emerald Bioscience Stock Performance

The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.59 and a current ratio of 3.59. The stock has a market cap of $177.01 million, a P/E ratio of -8.25 and a beta of 0.43.

About Emerald Bioscience

Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.